Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy

by Mark Roschewski and Daniel J. Hodson

Received: May 3, 2023.
Accepted: September 4, 2023.

Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy

Mark Roschewski¹ and Daniel J. Hodson²

¹Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, United States; Email: mark.roschewski@nih.gov

²Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom Email: djh1002@cam.ac.uk

Abstract word count: 248 (250 max)
Manuscript word count: 5055 (5000 max)
Figures: 1
Tables: 3
Running title: Biology and targeted therapy for CNS lymphoma
Keywords: diffuse large B-cell lymphoma, primary CNS lymphoma, PCNSL, secondary CNS lymphoma, SCNSL, molecular subtypes, targeted therapy

AUTHOR CONTRIBUTIONS
M.R and D.J.H. contributed equally to this manuscript.

CONFLICTS OF INTERESTS
The authors report no conflicts of interest.

ACKNOWLEDGEMENTS
The authors would like to thank patients and their families who participate in clinical trials testing novel agents in CNS lymphoma. DJH was supported by a Fellowship from CRUK (RCCFEL\100072). Research in the Hodson group is funded in part by the Wellcome Trust who support the Wellcome-MRC Cambridge Stem Cell Institute (203151/Z/16/Z), the CRUK Cambridge Major Centre (C49940/A25117) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) (the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care).
Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable for all patients, and older patients have fewer effective treatment options. Patients with relapsed or chemotherapy-refractory disease have a grave prognosis. Secondary CNS lymphoma (SCNSL) describes aggressive lymphomas involving the CNS at initial presentation or relapses within the CNS after treatment for systemic DLBCL. Isolated CNS relapse is often managed as PCNSL, but patients with synchronous involvement of DLBCL in both the periphery and the CNS pose a unique clinical challenge. Insights into the molecular circuitry of DLBCL have identified distinct genetic subtypes including cases with a predilection for CNS invasion. PCNSL and subsets of SCNSL are characterised by chronically activated B-cell receptor and NFKB signalling along with genetic evidence of immune evasion which may be exploited therapeutically. Improved mechanistic understanding of targetable pathways underpinning CNS lymphomas has led to numerous clinical trials testing targeted agent combinations and immunotherapy approaches with promising early results. Biologically rational strategies may further improve the cure rate of CNS lymphomas either by overcoming intrinsic or acquired treatment resistance.
and/or by being broadly applicable to patients of all ages.

I. INTRODUCTION

Diffuse large B-cell lymphoma (DLBCL) is a spectrum of aggressive B-cell lymphomas with remarkable clinical and molecular heterogeneity. These tumours manifest in myriad clinical presentations, including involvement of the central nervous system (CNS). Importantly, DLBCL can be cured with immunochemotherapy, even in advanced stages and after relapse.

Primary DLBCL of the CNS (PCNSL) is a rare subtype of DLBCL that involves the brain, eyes, leptomeninges, or spinal cord without evidence of systemic involvement. It accounts for 6% of all new CNS tumours with an annual incidence of ~1,500 cases in the United States. The incidence is rising in patients with advanced age, particularly those aged ≥75 years. Frontline treatment for PCNSL varies across institutions, but patients deemed suitable for dose-intensive therapy receive one of several high-dose methotrexate (HD-MTX)-based regimens and consolidation with either autologous stem cell transplantation (ASCT), radiotherapy, or cytarabine-based chemotherapy. No consensus exists regarding the optimal induction regimen and treatment guidelines rely almost exclusively on phase II clinical trials. Further, the cure rate may not be evident when surrogate markers for survival are used since late recurrences are not uncommon. Patients deemed unsuitable for HD-MTX, including those with advanced age or co-morbid conditions, are treated with reduced doses of chemotherapy with palliative intent. Notably, patients with
chemotherapy-refractory disease have a grave prognosis although it is unclear if these poor clinical results are due to intrinsic chemotherapy resistance, ineffective drug delivery, or a combination.\textsuperscript{14} Whilst good results are seen in patients able to tolerate dose-intensive therapy, the rising proportion of older patients means that most patients with PCNSL will die of lymphoma, and novel treatment approaches are needed.

Secondary CNS lymphoma (SCNSL) is distinguished from PCNSL as either synchronous CNS and systemic involvement of lymphoma or an isolated CNS relapse. SCNSL is not a specific biologic entity but most cases are DLBCL. The incidence of CNS involvement at diagnosis for DLBCL is only \textasciitilde5\%, but CNS progression may arise shortly after or during initial therapy.\textsuperscript{15} In a retrospective study of SCNSL, the majority (87\%) occurred at the time of first relapse and 39\% had synchronous systemic relapse.\textsuperscript{16} The prognosis of SCNSL is poor, so emphasis has been placed on prevention with intrathecal chemotherapy or HD-MTX prophylaxis delivered with frontline therapy in high-risk patients, but these strategies are not very effective and remain controversial.\textsuperscript{17,18} Further, patients with CNS involvement are often unnecessarily excluded from clinical trials testing novel approaches, even when the agents are effective for CNS disease. Overall, few effective treatments exist for SCNSL, and it remains an unmet clinical need.

We highlight advances in our understanding of the molecular pathogenesis of primary and secondary DLBCL of the CNS, including aspects of biology that are shared with genetic subtypes of DLBCL and the oncogenic pathways that are emerging as therapeutic targets. We discuss the treatment
landscape of CNS lymphomas and emphasize targeted agents with the strongest biologic rationale.

II. STANDARD APPROACH TO DLBCL INVOLVING THE CNS

Treatment of Primary DLBCL of the Central Nervous System

The prognosis of PCNSL is significantly worse than systemic DLBCL. Although induction therapy achieves remission in ~50% of patients, the risk of relapse remains unacceptably high without consolidation. Further, both induction therapy and consolidation are associated with significant toxicities not tolerated by all patients. Clinical outcomes are worse in older patients, particularly in those who do not receive dose-intensive therapy. The most pressing clinical needs are to improve the efficacy of induction therapy to potentially obviate the need for consolidation and to develop effective alternative strategies for patients who are not suitable candidates for dose-intensive therapy.

The first therapy that improved clinical outcomes was whole brain radiotherapy (WBRT), but all patients relapsed and neurotoxicity was problematic. Thus, the original role of chemotherapy was to reduce reliance on WBRT. Indeed, when HD-MTX was added to WBRT, many patients deferred radiotherapy for an extended period of time. In this way, HD-MTX became the de facto cornerstone chemotherapeutic agent for PCNSL due to its reliable CNS penetration, not based on a strong biologic rationale for efficacy in DLBCL.

Combination chemotherapy regimens were subsequently developed to further reduce reliance on WBRT. A randomized phase 2 study demonstrated
that high-dose cytarabine added to HD-MTX improved the complete response rate to 46% compared to 18% with HD-MTX alone.\textsuperscript{22} Rituximab also has been used to improve the response rates of induction therapy. A multicenter phase II study compared HD-MTX-based induction regimens and found that patients treated with the HD-MTX and cytarabine backbone plus both rituximab and thiotepa (MATERIAL) had a complete response rate of 49% compared to 30% with rituximab added to HD-MTX backbone and 23% with HD-MTX backbone alone.\textsuperscript{7}

Another strategy has been to incorporate high-dose chemotherapy with ASCT as a consolidation strategy.\textsuperscript{23,24} This strategy can be effective for long term disease control, but results vary depending on the conditioning regimen used. A retrospective registry study showed that patients who received thiotepa/busulfan/cyclophosphamide (TBC) or thiotepa/carmustine (TT-BCNU) conditioning had superior 3-year progression free survival compared to those who received carmustine, etoposide, cytarabine, melphalan (BEAM) conditioning.\textsuperscript{25} This improved efficacy, however, came at the cost of increased toxicity and non-relapse mortality with TBC. Indeed, a randomized phase 2 study in 140 patients with PCNSL under age 60 years compared thiotepa-based conditioning followed by ASCT to WBRT as a consolidation strategy and the 8-year event-free survival was 67% versus 39% (P=0.03) in favor of ASCT.\textsuperscript{5} Selected older patients without co-morbidities may be candidates for ASCT consolidation after careful considerations of the risks associated with this treatment.\textsuperscript{26} Ongoing trials are addressing the feasibility and efficacy of this approach.\textsuperscript{27}
Taken together, these studies strongly suggest that HD-MTX based induction regimens with ASCT consolidation improve clinical outcomes compared to WBRT consolidation in younger patients. Further, the ability of these regimens to cure PCNSL without consolidation is limited, and few effective alternative treatment options exist.

**Treatment of Secondary DLBCL of the Central Nervous System**

Compared to systemic DLBCL, the outcomes for SCNSL are significantly worse with an expected survival of <6 months.\(^{16,28}\) Patients with synchronous CNS and systemic involvement are particularly challenging since therapy needs to be both effective for systemic DLBCL and penetrate the blood-brain barrier.

In a large retrospective series, the 2-year survival rate for SCNSL was only 20\%, but patients deemed eligible for dose-intensive therapy had a 2-year survival rate of 62\%.\(^{16}\) Patients with isolated CNS disease may have a better prognosis; a series of 113 patients with isolated CNS relapse demonstrated that a subset of patients could survive for more than 2.5 years, but ultimately most patients died from lymphoma.\(^{29}\) In patients with synchronous DLBCL involving the CNS and periphery, clinical outcomes are largely related to the ability to control the CNS disease.\(^{30}\) A retrospective series of 80 patients with synchronous systemic DLBCL and CNS involvement demonstrated a 2-year OS of 49\%. Patients treated with dose-intensive regimens had a superior 2-year PFS compared to those treated with less intensive therapy 50\% vs. 31\% (p=0.006), respectively. Notably, the 2-year OS of patients with relapse in the CNS was
significantly worse than those with systemic relapse, respectively (13% vs. 36%, p=0.02).

The potential benefit of ASCT for SCNSL is also restricted to younger patients and the supporting data comes mostly from retrospective case series. A prospective multicenter phase 2 study of 79 patients with SCNSL tested alternating cycles of the MATRix regimen with rituximab, ifosfamide, carboplatin, etoposide (R-ICE) and responding patients received ASCT consolidation. In this study, only 37 (47%) patients received an ASCT. Indeed, this strategy should be considered for suitable candidates, but is largely restricted to younger patients and those without co-morbidities.

III. MOLECULAR BIOLOGY OF PCNSL and SCNSL

DLBCL arises from the malignant transformation of B lymphocytes that are either engaged in, or exiting, the germinal centre (GC) reaction. GCs are transient microanatomic structures that form in secondary lymphoid tissue in response to antigenic stimulation, where GC B cells undergo somatic hypermutation of their immunoglobulin genes associated with intense competition for T cell prior to differentiation into plasma or memory B cells. As such, systemic DLBCL typically develops within lymphoid tissue and tumour cells remain reliant on the lymph node microenvironment. This presents a biological challenge for CNS lymphomas, since GCs are not found within the CNS, and the usual supportive microenvironment of the lymph node is absent. Whilst SCNSL represents spread from cells that initiated as systemic DLBCL, the case of
PCNSL is even more intriguing since these cases lack evidence of lymphoma outside of the CNS, and relapses are almost universally restricted to the CNS. The question of how and where these tumours initiate, and how they survive or even depend upon the microenvironment of the CNS are key to understanding how biology might ultimately direct the therapy of CNS lymphomas. Two simplistic “pull or push” hypotheses can be formed: first the pull of some survival factor exclusive to the CNS, to which tumour cells are addicted; or second, the push from outside the CNS of some factor which tumour cells are unable to tolerate. Research over the last two decades, reinforced by recent genomic studies, suggest that both play a role in terms of neural-specific antigen within the CNS and host antitumour immunity outside the CNS. These studies highlight vulnerabilities that might be exploited for the biologically directed therapy of CNS lymphomas. We will predominantly consider CNS lymphomas that arise within immunocompetent patients, since these are a biologically homogeneous group, but also highlight important contrast with the biology of CNS lymphomas in the immune deficient patient. We will focus on aspects of the biology that have the greatest therapeutic relevance.

**PCNSL shares molecular biology with specific DLBCL subtypes**

DLBCL can be classified by gene expression profiling into subtypes that resemble either GC B cells (GCB DLBCL) or *in vitro* activated B cells (ABC DLBCL) and more recently genetic subtypes have emerged. Early work using immunohistochemistry showed that the majority of PCNSL cases could be
classified as ABC DLBCL\textsuperscript{40}, a finding borne out by transcriptional analysis using Nanostring.\textsuperscript{41} Early studies also revealed that PCNSL was enriched for mutations associated with ABC DLBCL. These included mutation of \textit{MYD88}, \textit{CD79B}, \textit{TBL1XR1}, \textit{PIM1} and deletions of the \textit{CDKN2A} and HLA loci.\textsuperscript{42-46} Since the advent of next generation sequencing technologies, more than 250 PCNSL exomes or whole genomes have now been published.\textsuperscript{47-52} Four main conclusions\textsuperscript{51}, summarised from across all these studies, capture the unique biological aspects of PCNSL: 1) an extremely high frequency of \textit{MYD88} (67 to 86%) and \textit{CD79B} (61%) mutations, implicating corrupted toll-like receptor (TLR) and B cell receptor (BCR) signalling as a mechanism of enhanced NFKB activity; 2) frequent mutations that impede onward differentiation and lock tumour cells into a GC-like proliferative state, including mutation of \textit{TBL1XR1}, \textit{PRDM1} and translocation of \textit{BCL6}; 3) the near universal loss of negative regulator of cell cycle, \textit{CDKN2A}, with only rare mutation of \textit{TP53}; and 4) the very high frequency of mutations that lead to immune evasion, including deletion of HLA loci, or mutation of \textit{B2M} or \textit{CD58}.

Intriguingly, this genomic profile is shared with other forms of extranodal lymphoma such as primary DLBCL of the testis, breast and skin.\textsuperscript{39,53} Moreover, this genetic profile of PCNSL, aligns precisely to a specific subtype of systemic DLBCL, variably termed C5, MCD or MYD88, identified from DLBCL genetic clustering studies.\textsuperscript{36-39} The C5/MCD/MYD88 subtype is characterised by BCR/TLR activation and immune evasion and is strongly enriched for cases with extranodal involvement. Where genetic classifiers such as LymphGen have been
applied to cases of PCNSL, almost all classified cases are found to fall within the MCD subtype.\textsuperscript{39} This suggests overlap between PCNSL and systemic MCD DLBCL in terms of biology, but also therapeutically exploitable vulnerabilities.

**Addiction to chronic active B cell receptor signalling**

The strikingly high frequency of \textit{MYD88} and \textit{CD79} mutations points strongly to oncogenic NFKB signalling as a critical driver of PCNSL. These mutations affect specific hotspots, resulting in a leucine to proline change at amino acid 265 in MYD88 (L265P) and the exchange of tyrosine 196 in CD79B. The function of these hotspot mutations is already well established from the study of ABC DLBCL. MYD88 is an adapter protein that is activated downstream of the toll-like receptor TLR9. It supports the assembly of a signalling complex that also includes IRAK 1 and IRAK4, thereby promoting activation of NFKB, and further enhanced by the L265P mutation.\textsuperscript{54} CD79B forms a heterodimer with CD79A to create the signalling component of the B cell antigen receptor. Tyrosine 196 sits within the immunoreceptor tyrosine-based activation motif (ITAM) and its mutation interrupts a negative feedback pathway, contributing to a hyperactive signalling state termed chronic active BCR signalling.\textsuperscript{55} For reasons that remain elusive, this state of chronic active BCR signalling appears is almost always associated with the IgM isotype. Despite strong expression of the class switching enzyme activation induced cytidine deaminase (AID), PCNSL show blocked class switch recombination and retaining expression of surface IgM.\textsuperscript{56} MYD88, TLR9 and the IgM BCR have been found to associate into a multiprotein, oncogenic supercomplex known as the My-T-BCR, which drives
activation of NFkB in DLBCL. Consistent with the frequent double mutation of MYD88 and CD79B, the oncogenic My-T-BCR complex was strongly detected in biopsies of PCNSL suggesting it to be a critical driver of oncogenic NFkB activity in PCNSL. Importantly, the formation of this complex depends upon an active BCR signal and can be blocked by pharmacological inhibitors of BCR signalling such as ibrutinib, highlighting a potential therapeutic vulnerability in PCNSL.

In ABC DLBCL, CD79B ITAM mutations are frequently associated with a BCR signal that is initiated by engagement of autoantigen. Mouse models show how combined CD79B and MYD88 mutation allows autoreactive B cells to escape deletion. Together with the strict tissue tropism seen in PCNSL, this has opened questions to whether PCNSL might receive chronic BCR stimulation from a neural-specific autoantigen. In support of this, PCNSL shows strong bias towards usage of the immunoglobulin variable gene segment VH4-34, which encodes polyreactive or autoreactive immunoglobulin. Moreover, PCNSL immunoglobulin genes show heavy somatic hypermutation that is biased towards codon-altering but non-destructive mutations, a pattern suggesting antigen driven selection. Production of recombinant antibody based upon PCNSL immunoglobulin V gene sequences confirm that these antibodies are polyreactive and bind CNS proteins. Moreover, comparison of tumour sequences with the predicted naïve BCR, showed that somatic hypermutation further increased self-reactivity, suggesting that immunoglobulin variants are selected based on their interaction with neural autoantigen. Protein microarrays have identified putative interacting neural antigens. Whilst PCNSL-derived recombinant antibodies failed
to recognise common autoantigens, they showed reactivity to a large range of CNS-specific antigens.\textsuperscript{63}

Overall, these studies reveal the reliance of PCNSL on chronic activated signalling through the BCR. This may provide a partial explanation for the unique CNS trophism of PCNSL, but it also reveals an important tumour vulnerability that might be exploited by pharmacological inhibitors of the BCR pathway.

**Heightened sensitivity to antitumour immunity.**

Despite their location in an immune privileged site, PCNSL cells remain under strong selective pressure from the immune system. Although the need to escape immune recognition is shared with systemic DLBCL, one of the most striking features of PCNSL is the almost universal presence of genetic alterations that promote immune evasion.\textsuperscript{64} This prominent immune vulnerability may be secondary to the high expression of the DNA mutator enzyme AID in PCNSL, which leads to ongoing aberrant somatic hypermutation and an increasing neoantigen burden.\textsuperscript{64,65}

Multiple studies show that most PCNSL tumours have lost expression of both MHC class I and class II.\textsuperscript{66-68} This results from deletions within the HLA locus on chromosome 6p, truncating mutations of individual HLA genes and in \textit{B2M}.\textsuperscript{52,53,65,69,70} Inactivating mutations of \textit{TAP1} and \textit{TAP2} are additional mechanisms that limit immunogenic peptide display on MHC.\textsuperscript{39,65} Loss of MHC renders tumour cells invisible to cytotoxic T cells that typically infiltrate the PCNSL tumour microenvironment.\textsuperscript{67} However, MHC I loss may render tumour cells susceptible to destruction by NK cells. CD58 is a cell surface antigen and
ligand for the receptor CD2, expressed on T cells and NK cells. CD58-CD2 ligation is essential for tumour lysis by T or NK cells and CD58 is commonly inactivated in DLBCL that has lost MHC I expression.\textsuperscript{71} Indeed, CD58 is mutated in over a third of PCNSL cases.\textsuperscript{65} Mutations of CD70 and CD80 represent other mechanisms used by PCNSL to avoid cytotoxic T cell killing.\textsuperscript{48,64,65}

An alternative immune evasion strategy is the expression of immune suppressive ligands such as PDL1 and PDL2, inducing an exhaustion phenotype in T cells. Copy number gains of 9p24.1, which contains the \textit{PDL1} and \textit{PDL2} loci, and structural variants of both loci leading to increased surface expression of PDL1 and PDL2 were reported in PCNSL.\textsuperscript{53} However, the impact of immune checkpoint ligands in PCNSL remains controversial as increased surface expression on tumour cells was not identified in other studies.\textsuperscript{50,68} Regardless of the mechanism, single cell transcriptomic analysis has revealed clear signatures of T cell exhaustion within the PCNSL microenvironment.\textsuperscript{72}

Overall, it appears that almost every case of PCNSL is associated with genetic evidence of immune evasion, highlighting a critical vulnerability. Whilst this raises enticing therapeutic possibilities, greater understanding is still required to define precisely which of these genetic alterations might render cells more or perhaps less sensitive to immunotherapeutic approaches.

**The enigmatic origins of PCNSL**

A fascinating enigma is the precise origin of PCNSL. DLBCL arises from a B cell engaged in or exiting the GC. In ABC DLBCL, a simplistic model of
malignant transformation includes NFkB activation to drive proliferation and survival, combined differentiation block, precluding cells from exiting the GC phenotype. Superficially, this fits with the genetics of PCNSL, including chronic BCR activation leading to oncogenic NFkB activation, and blocked plasma cell differentiation as a result of frequent BCL6 translocation, or genetic loss of PRDM1.53,65,73 Moreover, high levels of somatic hypermutation in the immunoglobulin genes support this post-GC origin of PCNSL.62 However, there is scant evidence for GC formation within the CNS, suggesting that this step may occur in peripheral lymphoid tissue, or alternatively reflects AID induction through a GC-independent process. A slightly different model has been proposed prompted by the high frequency of mutations in TBL1XR1. Mouse models show how mutant TBL1XR1 drives B cells towards a memory B (MB) fate.74 TBL1XR1 mutant MB cells are unable to differentiate to plasma cells but instead undergo repeated cycles of re-entry into the GC reaction upon subsequent antigen exposure. Mouse models show how MB differentiation is also promoted by MYD88 mutation. Of particular relevance to PCNSL, these mice develop increased self-reactive MB cells that can be stimulated to reactivate and proliferate with minimal T cell co-stimulation.75 Therefore the genetics of PCNSL suggest a model where mutant, polyreactive MB engage neural-specific autoantigen outside a formal GC environment, which drives cellular activation, proliferation, upregulated AID expression and subsequent somatic hypermutation, leading to enhanced autoantigen recognition and malignant transformation in the CNS.76 The point at which B cells enter the CNS during this
process of malignant transformation remains unclear. However, it is notable that

*MYD88* mutant, non-tumour cells were detected in peripheral blood in PCNSL patients, suggesting this is an early initiating mutation that occurs outside the CNS. The distinction is of significance as the early transformed cell may represent a common precursor cell (CPC) that seeds relapse and may be the source of late relapses.

**Comparison to SCNSL and immune deficient CNS lymphomas**

Whilst PCNSL in the immunocompetent patient represents a comparatively homogeneous entity as described above, SCNSL and PCNSL arising in the context of immune deficiency show important biological differences. Gandhi et al studied the genetics of PCNSL in immune deficient patients, most associated with EBV infection. In contrast to the genetic profile of immune competent patients, almost all cases lacked mutation of *MYD88* and *CD79B*. Moreover, most cases retained surface HLA expression. There was evidence of an induced immune tolerant microenvironment with increased macrophage infiltration and increased expression of PDL1 and PDL2 on the surface of microenvironmental cells. These findings suggest that EBV may itself drive NFkB activation and immune evasion without the need for the genetic alterations seen in immune competent PCNSL. SCNSL also shows important distinctions. Whilst PCNSL is almost always classified to the ABC subtype of DLBCL, SCNSL covers a more diverse spectrum of biology comprising an equal division of ABC and GCB subtypes. Systemic DLBCL of the MCD genetic subtype is associated
with extranodal involvement, including sites such as kidney and adrenal considered to be of high risk for CNS recurrence. MCD DLBCL with secondary CNS involvement may share considerable overlap with PCNSL. However, GCB DLBCL with CNS involvement represents a different biological entity. For example, whilst MYC and BCL2 proteins are highly expressed, translocation of these loci is rarely seen in PCNSL. In contrast, translocation of MYC and/or BCL2 is enriched in GCB DLBCL involving the CNS. Indeed, MYC translocated lymphoma including high-grade B-cell lymphomas with double-hit and Burkitt lymphoma have an increased risk of CNS involvement. The important implication of all these contrasts is that biologically directed, therapeutic vulnerabilities of CNS lymphomas may differ depending on whether tumours arise as true PCNSL or alternatively in the context of immune deficiency or secondary to systemic disease.

Multiple studies have collectively made tremendous progress in dissecting the biology of CNS lymphomas. They paint a picture of PCNSL as a homogeneous biological entity, which like systemic MCD DLBCL, is characterised by chronically activated BCR and NFKB signalling combined with a pronounced requirement for immune evasion. This phenotype presents a specific set of therapeutic vulnerabilities, many of which are already being tested in clinical trials. Yet, important biological differences exist between true PCNSL and other forms of CNS lymphoma that may require a different treatment approach.

IV. RATIONAL TARGETED AGENTS FOR CNS LYMPHOMAS
The critical question then becomes whether the improved mechanistic understanding of the therapeutic vulnerabilities of CNS lymphomas can be translated to improve clinical outcomes. To this end, rational targeted agents and combinations have been tested in prospective trials (Tables 1-2). Notably, targeted agents have been given on indefinite treatment schedules which may increase the toxicity over time. To reduce treatment duration and improve efficacy, many ongoing clinical trials are testing novel combinations with fixed duration treatment schedules (Table 3).

Clinical studies in systemic DLBCL first demonstrated that the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib inhibits chronic active BCR signaling and has selective activity in ABC DLBCL tumours that harbor both MYD88<sup>L265P</sup> and CD79B mutations. Given that this genetic profile is common in PCNSL and subsets of SCNSL, BTK is a highly rational therapeutic target in CNS lymphomas and multiple inhibitors of BTK are being tested.

Another class of rational targeted agents are the immunomodulatory drugs, lenalidomide and pomalidomide, which exert direct cytotoxic effects, recruitment of NK cells, upregulation of CD80 and CD40, impairment of inflammatory cytokines, and effects on the tumour microenvironment. Lenalidomide downregulates the transcription factor interferon regulatory factor 4 (IRF4) and augments interferon β production to kill ABC DLBCL cell lines in vitro. Further, pre-clinical models have demonstrated synergy between lenalidomide and ibrutinib to inhibit NFkB signaling in ABC DLBCL cell lines.
A third rational strategy involves various forms of immunotherapy, including immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells. Given the increased surface expression of PDL1 and PDL2 in PCNSL, targeting the PD-1 receptor has a biologic basis. CAR-T-cell therapy is also rational for CNS lymphomas since this approach has efficacy in chemotherapy-refractory systemic DLBCL, but it remains unknown if the underlying genetic basis promoting immune evasion in CNS lymphomas will limit the efficacy of these approaches.

**Targeted Agents as Monotherapy for CNS lymphomas**

A fundamental limitation of monotherapy for CNS lymphomas is rapid onset of drug resistance, as observed in systemic DLBCL. Indeed, despite remarkably high initial response rates, the responses after BTK monotherapy are often incomplete, and durability of responses are short. In a phase 1 study, escalating doses of ibrutinib monotherapy was given to 20 patients with relapsed or refractory PCNSL (N=13) and SCNSL (N=7). The clinical activity of ibrutinib was excellent and 10 (77%) PCNSL patients responded, including 5 (38%) who achieved a complete response. Yet, the durability of response was short and the median PFS was 4.6 months. The clinical activity of ibrutinib for SCNSL was also tested and 5 (71%) patients responded, including 4 (57%) complete responses; but the median PFS was 7.4 months. A multicenter phase 2 study tested ibrutinib in 52 patients with relapsed or refractory PCNSL and 27 (52%) patients responded including 10 (19%) complete responses but the median PFS was 3.3
months. Taken together, these data show that ibrutinib is highly active in PCNSL, and probably subsets of SCNSL, but resistance develops quickly to monotherapy.

In a phase 1 study, 14 patients with relapsed or refractory CNS lymphoma received lenalidomide at escalating doses and 6 (86%) patients with PCNSL responded including 1 (14%) complete response. In SCNSL, 4 (57%) responses were observed, including 2 (29%) complete responses. The duration of responses was variable, but included 4 responses lasting ≥12 months.

A retrospective series of 4 patients with relapsed and refractory CNS lymphoma treated with the immune checkpoint inhibitor nivolumab demonstrated clinical responses in all patients. Two ongoing phase 2 studies of PD-1 inhibitors as monotherapy are ongoing and have yet to publish clinical results.

**Combination Targeted Therapy for CNS lymphomas**

In order to overcome the drug resistance that rapidly occurs after monotherapy, prospective clinical trials have tested combination regimens for CNS lymphoma. In a phase 1 study, patients with relapsed or refractory PCNSL (n=13) and untreated PCNSL (n=5) were treated with escalating doses of ibrutinib monotherapy along with temozolomide, etoposide, doxil, dexamethasone, and rituximab (TEDDi-R) and most patients achieved a complete response including patients refractory to HD-MTX-based regimens. A follow-up report on this small series suggest that remissions were often durable. A major limitation of this regimen was the risk of developing
aspergillosis infections when no antifungal prophylaxis was given. This regimen has been revised to include anti-fungal prophylaxis and is being studied in both PCNSL and SCNSL [NCT02203526 and NCT03964090].

Ibrutinib has also been safely added to HD-MTX and rituximab in CNS lymphomas. In a phase 1b study, 15 patients with relapsed PCNSL (n=9), relapsed SCNSL (n=3), and untreated SCNSL (n=3) received HD-MTX, rituximab, and ibrutinib. No unexpected toxicities were observed and no cases of aspergillosis were reported. In PCNSL, 8 (89%) patients responded, including 6 (67%) complete responses. The durability of response to the regimen was unclear as 4 of the responding patients received ASCT consolidation. In 4 cases without consolidation, 3 remained in remission >10 months. In SCNSL, 4 (67%) patients responded and 2 (33%) achieved a complete response. Two responding patients progressed after a remission of < 6 months, 1 received an ASCT, and 1 had an ongoing remission of 6 months. Numberous combination regimens using ibrutinib and well as second generation BTK inhibitors including zanubrutinib, acalabrutinib, tirabrutinib and orelabrutinib are now being tested in ongoing clinical trials.

Lenalidomide and pomalidomide have both been tested as combination therapy for relapsed or refractory PCNSL. In a multicenter phase 2 study, 50 patients with relapsed or refractory PCNSL received lenalidomide and rituximab for 8 cycles and responding patients continued lenalidomide monotherapy for another 12 cycles. The overall response rate was 32% including 13 (29%) complete responses, but the median PFS was only 7.8 months. In a phase 1
study, escalating doses of pomalidomide were tested in combination with
dexamethasone for 2 cycles followed by pomalidomide monotherapy until
disease progression. In 25 evaluable patients, the overall response rate was
48% including 8 (32%) complete responses. The median PFS for this study was
5.3 months. Taken together, these results support immunomodulatory agents as
clinically active and biologically rational targeted agents for CNS lymphomas that
will likely will be most effective as part of combination therapy.

CAR-T therapies targeting CD19 can overcome chemotherapy resistance
in systemic DLBCL, and have been tested in small studies for CNS
lymphoma. One concern about CAR-T for CNS lymphomas is related to a
potential increased incidence of immune cell associated neurotoxicity syndrome
(ICANS). In a pilot study of 12 patients with PCNSL, tisagenlecleucel resulted in
a response in 7 (58%) patients including 6 (50%) with a complete response.
Notably, only 1 patient had grade 3 ICANS. In another pilot study of
axicabtagene ciloleucel in 6 patients with PCNSL and 3 patients with SCNSL,
complete responses were seen in 6 (86%) patients with 3 months of follow-up
and only 1 case of grade 3 or higher ICANS. These results suggest that effector
CAR-T cells cross the blood brain barrier and can induce remissions in CNS
lymphoma. Indeed, a meta-analysis of 128 patients with CNS lymphoma
suggested that the safety and efficacy of anti-CD19 CAR-T therapy is similar to
that observed in systemic DLBCL. These strategies have only very short follow-
up and many questions remain regarding persistence of CAR T-cells in the CSF,
mechanisms of treatment failure, and if biologic differences between PCNSL and SCNSL will impact treatment efficacy.

V. FUNDAMENTAL QUESTIONS AND FUTURE DIRECTIONS

Primary and secondary DLBCL involving the CNS pose unique clinical challenges regarding delivery of therapy into tumour tissue, treatment-related toxicities, and diversity of underlying biology. Recent insights regarding the molecular biology of PCNSL and DLBCL subsets with CNS predilection along with an expanding list of effective targeted agents have introduced important fundamental questions that require prospective clinical trials to answer. What are the safest and most effective targeted agents for CNS lymphoma and which combinations are tolerable in patients of all ages? Will predictive biomarkers based on underlying biology be identified and be reliable enough to select therapy? Will technological advances such as next-generation sequencing of cell-free DNA in the plasma and/or CSF aid in clinical decision-making?99 Well-designed clinical trials with strong translational molecular endpoints will be essential to address these questions and ultimately improve the cure rate of CNS lymphoma.
REFERENCES


<table>
<thead>
<tr>
<th>Novel Mechanism</th>
<th>Novel Agent</th>
<th>Design</th>
<th>Study population (# of patients)</th>
<th>Response rate</th>
<th>Response Duration</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inhibitor of BTK</strong></td>
<td>Ibrutinib</td>
<td>Phase 1</td>
<td>PCNSL, relapsed (n=13)</td>
<td>ORR: 77% CR: 38%</td>
<td>Median PFS 4.6 mo</td>
<td>Grommes et al. [87]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SCNSL, relapsed (n=7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ORR: 71% CR/CRu: 57%</td>
<td>Median PFS 7.4 mo</td>
<td></td>
</tr>
<tr>
<td>Ibrutinib</td>
<td>Phase 2</td>
<td>PCNSL, relapsed (n=52)</td>
<td>ORR: 52% CR/CRu: 19%</td>
<td>Median PFS 4.8 mo</td>
<td>Soussain et al. [88]</td>
<td></td>
</tr>
<tr>
<td><strong>Tirabrutinib</strong></td>
<td>Phase 2</td>
<td>PCNSL, relapsed (N=44)</td>
<td>ORR: 64% CR/CRu: 34%</td>
<td>Median PFS 2.9 mo</td>
<td>Narita et al. [79]</td>
<td></td>
</tr>
<tr>
<td><strong>Immunomodulatory</strong></td>
<td>Lenalidomide</td>
<td>Phase 1</td>
<td>PCNSL, relapsed (n=7)</td>
<td>ORR: 86% CR: 14%</td>
<td>PFS not reported</td>
<td>Rubenstein et al. [89]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SCNSL, relapsed (n=7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ORR: 57% CR/CRu: 29%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inhibitor of mTOR</strong></td>
<td>Temsirolimus</td>
<td>Phase 2</td>
<td>PCNSL, relapsed (n=37)</td>
<td>ORR: 54% CR/CRu: 22%</td>
<td>Median PFS 2.1 mo</td>
<td>Korfel et al. [86]</td>
</tr>
</tbody>
</table>

Abbreviations: CNS, central nervous system; PCNSL, primary CNS lymphoma; SCNSL, secondary CNS lymphoma; BTK, Bruton’s Tyrosine Kinase; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase
## Table 2. Prospective Studies of Novel Targeted Agents as Combination Therapy in CNS Lymphomas

<table>
<thead>
<tr>
<th>Novel Mechanism</th>
<th>Targeted Agent</th>
<th>Design</th>
<th>Study population (# of patients)</th>
<th>Response rate</th>
<th>Response Duration</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inhibitor of BTK</strong></td>
<td>Ibrutinib + TEDD-R</td>
<td>Phase 1</td>
<td>PCNSL (n=18)</td>
<td>ORR: 94%</td>
<td>CR/CRu: 86%</td>
<td>Lionakis et al.91</td>
</tr>
<tr>
<td></td>
<td>Ibrutinib + HD-MTX-R</td>
<td>Phase 1</td>
<td>SCNSL (n=6)</td>
<td>ORR: 89%</td>
<td>CR/CRu: 67%</td>
<td>Grommes et al.93</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PCNSL (n=9)</td>
<td>ORR: 67%</td>
<td>CR/CRu: 33%</td>
<td></td>
</tr>
<tr>
<td><strong>Immunomodulator</strong></td>
<td>Lenalidomide + Rituximab</td>
<td>Phase 2</td>
<td>PCNSL (n=50)</td>
<td>ORR: 32%</td>
<td>CR/CRu: 29%</td>
<td>Soussain et al.94</td>
</tr>
<tr>
<td></td>
<td>Pomalidomide + Dexamethasone</td>
<td>Phase 1</td>
<td>PCNSL (n=25)</td>
<td>ORR: 48%</td>
<td>CR/CRu: 32%</td>
<td>Tun et al.95</td>
</tr>
</tbody>
</table>

Abbreviations: CNS, central nervous system; BTK, Bruton's Tyrosine Kinase; TEDD-R (temozolomide, etoposide, doxil, dexamethasone, rituximab); PCNSL, primary CNS lymphoma; SCNSL, secondary CNS lymphoma; ORR, overall response rate; CR, complete response; CRu, complete response undetermined; PFS, progression-free survival; HD-MTX-R, high-dose methotrexate and rituximab;
Table 3. Ongoing Clinical Trials Testing Novel Targeted Agents or Combinations in CNS Lymphomas

<table>
<thead>
<tr>
<th>Novel mechanism</th>
<th>Targeted agent Combination</th>
<th>Design</th>
<th>Study population</th>
<th>Target Enrollment</th>
<th>Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhibitor of BTK</td>
<td>Zanubrutinib</td>
<td>Phase 2</td>
<td>PCNSL and SCNSL, relapsed</td>
<td>20</td>
<td>NCT05117814</td>
</tr>
<tr>
<td>Inhibitor of BTK + chemotherapy</td>
<td>Ibrutinib + TEDD-R</td>
<td>Phase 1</td>
<td>PCNSL, relapsed and untreated</td>
<td>40</td>
<td>NCT02203526</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ibrutinib + TEDD-R</td>
<td>Phase 2</td>
<td>SCNSL, relapsed and untreated</td>
<td>32</td>
<td>NCT03964090</td>
</tr>
<tr>
<td>1) Ibrutinib + MER</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2) Lenalidomide + MER</td>
<td></td>
<td>Randomized</td>
<td>PCNSL, relapsed</td>
<td>120</td>
<td>NCT04129710</td>
</tr>
<tr>
<td>3) MER</td>
<td></td>
<td>Phase 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Orelabrutinib + MR</td>
<td>Phase 2</td>
<td>PCNSL, untreated</td>
<td>Not reported</td>
<td>Ma et al.(^{81})</td>
</tr>
<tr>
<td></td>
<td>Tirabrutinib + MTR or R-MVP</td>
<td>Phase 2</td>
<td>PCNSL, untreated</td>
<td>112</td>
<td>NCT04947319</td>
</tr>
<tr>
<td>Inhibitor of BTK + Immunomodulator + chemotherapy</td>
<td>Zanubrutinib + Lenalidomide + MTR</td>
<td>Phase 2</td>
<td>PCNSL, untreated</td>
<td>40</td>
<td>Song el al.80</td>
</tr>
<tr>
<td>Inhibitor of BTK + Inhibitor of PI3K</td>
<td>Ibrutinib + Copanlisib</td>
<td>Phase 1</td>
<td>PCNSL, relapsed</td>
<td>45</td>
<td>NCT03581942</td>
</tr>
<tr>
<td>Inhibitor of BTK + Immunomodulator</td>
<td>Ibrutinib + Lenalidomide + Rituximab</td>
<td>Phase 1b</td>
<td>PCNSL and SCNSL, relapsed</td>
<td>40</td>
<td>NCT03703167</td>
</tr>
<tr>
<td>Inhibitor of BTK + Immunomodulator + Inhibitor of BCL2</td>
<td>Venetoclax, ibrutinib, prednisone, Obinutuzumab, Revlimid</td>
<td>Phase 1</td>
<td>PCNSL and SCNSL, relapsed and untreated</td>
<td>10</td>
<td>NCT05211336</td>
</tr>
<tr>
<td>Inhibitor of PD-1</td>
<td>Nivolumab</td>
<td>Phase 2</td>
<td>PCNSL, relapsed</td>
<td>65</td>
<td>NCT02857426</td>
</tr>
<tr>
<td></td>
<td>Pembrolizumab</td>
<td>Phase 2</td>
<td>PCNSL and SCNSL, relapsed</td>
<td>52</td>
<td>NCT03255018</td>
</tr>
<tr>
<td>Inhibitor of BTK + Inhibitor of PD-1</td>
<td>Ibrutinib + Nivolumab</td>
<td>Phase 2</td>
<td>PCNSL and SCNSL, relapsed</td>
<td>40</td>
<td>NCT03770416</td>
</tr>
<tr>
<td></td>
<td>Acalabrutinib + Durvalumab</td>
<td>Phase 1</td>
<td>PCNSL and SCNSL, relapsed</td>
<td>21</td>
<td>NCT04462328</td>
</tr>
<tr>
<td>Immunomodulator + Inhibitor of PD-1</td>
<td>Pomalidomide + Nivolumab</td>
<td>Phase 1</td>
<td>PCNSL, relapsed</td>
<td>23</td>
<td>NCT03798314</td>
</tr>
</tbody>
</table>

Abbreviations: CNS, central nervous system; BTK, Bruton’s Tyrosine Kinase; TEDD-R (temozolomide, etoposide, doxil, dexamethasone, rituximab); PCNSL, primary CNS lymphoma; SCNSL, secondary CNS lymphoma; MER, high-dose methotrexate, etoposide, rituximab; MR, high-dose methotrexate, rituximab; MTR, high-dose methotrexate, temozolomide, rituximab; R-MVP, high-dose methotrexate, rituximab, procarbazine, vincristine; PI3K, phosphoinositide 3-kinase; PD-1, programmed death ligand
FIGURE LEGENDS

Figure 1. Four Biological Cornerstones of PCNSL Biology; 1) Chronic active BCR signaling driven by neural-specific autoantigen, activating mutations of MYD88 and CD79B, and formation of the MYD88-TLR9-BCR (My-T-BCR) complex. 2) Cell cycle activation secondary to deletion of the CDKN2A locus. 3) Escape from host immunity, resulting from loss of HLA expression, mutation of CD58 or enhanced expression of immune checkpoint ligands. 4) Transcription factor mutations (BCL6, PRDM1 and TBL1XR1) that block exit from, or promote reentry into, the germinal center phenotype of proliferation and ongoing hypermutation.